Zobrazeno 1 - 10
of 170
pro vyhledávání: '"TOMOHIDE TSUKAHARA"'
Autor:
Aiko Murai, Terufumi Kubo, Takayuki Ohkuri, Junko Yanagawa, Yuki Yajima, Akemi Kosaka, Dongliang Li, Toshihiro Nagato, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Takeshi Nagasaki, Yoshihiko Hirohashi, Hiroya Kobayashi, Toshihiko Torigoe
Publikováno v:
Immunological Medicine, Vol 47, Iss 2, Pp 93-99 (2024)
AbstractThe recognition by cytotoxic T cells (CTLs) is essential for the clearance of SARS-CoV-2 virus-infected cells. Several viral proteins have been described to be recognized by CTLs. Among them, the spike (S) protein is one of the immunogenic pr
Externí odkaz:
https://doaj.org/article/df5db71fc3a644528e48fd8244c2f187
Autor:
Kanta Hori, Shuhei Yamada, Kenji Murata, Haruka Miyata, Yuka Mizue, Aiko Murai, Tomoyuki Minowa, Kenta Sasaki, Naoki Shijubou, Terufumi Kubo, Rena Morita, Serina Tokita, Takayuki Kanaseki, Tomohide Tsukahara, Takashige Abe, Nobuo Shinohara, Yoshihiko Hirohashi, Toshihiko Torigoe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Adoptive T cell therapy, using T cell receptor-engineered T (TCR-T) cells and chimeric antigen receptor T (CAR-T) cells, is a potent immunotherapy option. Bladder cancer is a prevalent urological malignancy, particularly in cases of muscle invasion a
Externí odkaz:
https://doaj.org/article/269c9bd4b49446de98270f0bc2134d49
Autor:
Naoki Shijubou, Yuichiro Asai, Michiko Hosaka, Keiko Segawa, Terufumi Kubo, Masahiro Miyajima, Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, Kenji Murata, Atsushi Watanabe, Tadashi Hasegawa, Hirofumi Chiba, Toshihiko Torigoe
Publikováno v:
Immunological Medicine, Vol 46, Iss 2, Pp 93-96 (2023)
AbstractImmune checkpoint inhibitors (ICIs) for various types of malignancy, including non-small-cell lung cancer, have improved prognosis in some cases. Granuloma formation after ICI administration suggests a tumor antigen-specific cytotoxic T cell
Externí odkaz:
https://doaj.org/article/1a1984303116437c81aee308390fe45b
Autor:
Takashi Sasaya, Terufumi Kubo, Kenji Murata, Yuka Mizue, Kenta Sasaki, Junko Yanagawa, Makoto Imagawa, Hirotaka Kato, Tomohide Tsukahara, Takayuki Kanaseki, Yasuaki Tamura, Akihiro Miyazaki, Yoshihiko Hirohashi, Toshihiko Torigoe
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4605-4615 (2023)
Abstract Immune checkpoint inhibitor‐based cancer immunotherapy has provided an additional therapeutic option for oral squamous cell carcinoma (OSCC) with recurrence or distant metastases. However, further improvement of OSCC treatment is required
Externí odkaz:
https://doaj.org/article/305c824447da4fba820e6abd4c2eb271
Autor:
Sadahiro Iwabuchi, Tomohide Tsukahara, Toshitugu Okayama, Masahiro Kitabatake, Hideki Motobayashi, Shigeyuki Shichino, Tadashi Imafuku, Kenzaburo Yamaji, Kyohei Miyamoto, Shinobu Tamura, Satoshi Ueha, Toshihiro Ito, Shin-ichi Murata, Toshikazu Kondo, Kazuho Ikeo, Yutaka Suzuki, Kouji Matsushima, Michinori Kohara, Toshihiko Torigoe, Hiroki Yamaue, Shinichi Hashimoto
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being developed world over. We investigated the possibility of producing artificial antibodies from the formalin fixation and paraffin-embedding (FFP
Externí odkaz:
https://doaj.org/article/32149fe894984f60b5857c5a88f4c29c
Autor:
Terufumi Kubo, Sayuri Sato, Tokimasa Hida, Tomoyuki Minowa, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Hisashi Uhara, Toshihiko Torigoe
Publikováno v:
Immunity, Inflammation and Disease, Vol 9, Iss 3, Pp 734-745 (2021)
Abstract Background Barrier disruption and an excessive immune response in keratinocytes are now considered to have important roles in the pathophysiology of atopic dermatitis (AD). Furthermore, disturbed keratinocyte differentiation is considered to
Externí odkaz:
https://doaj.org/article/38156c2cf35646e2b075010a091cfa70
Autor:
Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita, Toshihiko Torigoe
Publikováno v:
Immunological Medicine, Vol 0, Iss 0, Pp 1-11 (2021)
Despite the considerable success of cancer immunotherapy with immune checkpoint inhibitors, their nonspecific release of the immunosuppressive mechanism is often associated with immune-related adverse events (irAEs). irAEs significantly disturb patie
Externí odkaz:
https://doaj.org/article/44d134e8443c48ef80f9d6ca498f209d
Autor:
Terufumi Kubo, Taro Sugawara, Tomoyo Shinkawa, Tomoyo Kurisu, Nodoka Kouzen, Toshiaki Tanaka, Fumimasa Fukuta, Kouji Yamasaki, Shintaro Sugita, Kazuhiko Matsuo, Rena Morita, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Tadashi Hasegawa, Naoya Masumori, Toshihiko Torigoe
Publikováno v:
Immunological Medicine, Vol 44, Iss 2, Pp 136-141 (2021)
Effective management of immune-related adverse events in patients receiving immunotherapy for cancer is problematic. In this report, we present the case of a 58-year-old man with advanced clear cell renal cell carcinoma who responded well to a combin
Externí odkaz:
https://doaj.org/article/df76912d07174c658434da11e8f06dbd
Autor:
Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Tadashi Hasegawa, Toshihiko Torigoe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 1940-1942 (2021)
The immune system is often called a double-edged sword, due to the inextricable link between cancer immunity and allergy/autoimmunity. Intriguingly, a growing number of cases have been reported in which PD-1 blockade triggers the exacerbation of tube
Externí odkaz:
https://doaj.org/article/305082245d6945e1a32a39e3177ea5ac
Autor:
Yohei Ueki, Masahiro Matsuki, Terufumi Kubo, Rena Morita, Yoshihiko Hirohashi, Syunsuke Sato, Ryota Horibe, Kazuhiko Matsuo, Tomohide Tsukahara, Takayuki Kanaseki, Yasunari Takakuwa, Masaaki Satoh, Naoki Itoh, Toshihiko Torigoe
Publikováno v:
IJU Case Reports, Vol 3, Iss 6, Pp 266-269 (2020)
Introduction Immune checkpoint inhibitors are now a standard therapeutic option for lung adenocarcinoma. However, Immune checkpoint inhibitors often induce various immune‐related adverse events. Case presentation The patient was a 78‐year‐old w
Externí odkaz:
https://doaj.org/article/f20c3594a9e24922ab0dbfcfbdd3dcf8